BlackSky Tech

BlackSky Technology rallied during the regular session, closing up 8.9% at $22.445, driven by its participation in the Canaccord Genuity Growth Conference and recent winning of a series of Gen-3 AI tactical ISR R&D contracts. The stock climbed steadily from its open of $21.22 to an intraday high of $22.46, with 361,618 shares traded. Q1 2026 revenue declined 29.7% YoY to $20.77 million, net loss widened to $29.66 million, and EPS was -$0.82, reflecting weak fundamentals. However, the stock remains below its 20-day MA of $23.80 and 60-day MA of $32.54, and is 57.6% off its 52-week high of $52.88, though YTD it has gained 7.8%.

BlackSky Technology closed regular trading down 5.18% at $21.60, driven by a sharp Q1 earnings deterioration: revenue fell 29.68% YoY to $20.774 million, net loss widened 131.51% to $29.663 million, and EPS of -$0.82 compared unfavorably to a -$0.0243 loss in Q4 2025. The stock surged to a pre-market high of $23.774 (ET 04:00) but opened at $22.67 on the regular session and steadily declined, hitting an intraday low of $21.60 (ET 09:55). The current price is 59.15% below the 52-week high of $52.88 and significantly below its 20-day ($24.938) and 60-day ($33.402) moving averages. Earlier positives such as Gen-3 AI tactical ISR R&D contracts and a Gen-2 capacity expansion deal failed to offset the weak earnings, while insider selling of over $1.0M added to bearish sentiment. However, the stock is still up 3.75% YTD with a small workforce of 321 employees.

BlackSky Technology opened the regular session at $22.83, dipped to an intraday low of $22.19, then rebounded to close at $23.00, up 5.2% from the prior close of $21.86, but well off the pre-market high of $25.22, exhibiting a spike-and-reversal pattern. The move was driven by the company's announcement of a Q2 2026 earnings call and a series of recent U.S. R&D contracts for Gen-3 AI tactical ISR operations. However, fundamentals remain under pressure: Q1 revenue fell 29.68% YoY to $20.77M, net loss widened to $29.66M, with EPS of -$0.82 and ROE of -135.08%. The stock is still 56.51% below its 52-week high of $52.88 and trades below both the 20-day ($25.39) and 60-day ($33.92) moving averages, with a YTD gain of only 10.47%. While the recent contract wins provide a positive catalyst, insider selling of over $1.0M and a Jefferies downgrade to Hold temper the outlook.

BKSY staged a sharp intraday rally today, driven by the announcement of a Q2 2026 earnings call that attracted market attention. The stock surged from a session low of $20.355 to a high of $22.540, closing up 5.1% and fully erasing pre-market losses. However, Q1 revenue fell 29.68% YoY to $20.77 million, net loss widened to $29.66 million, and EPS of -$0.8205 worsened 97.32% YoY, highlighting persistent fundamental challenges. At $22.54, the stock remains 57.38% below its 52-week high of $52.88, well below the 20-day MA of $26.038 and 60-day MA of $34.491, with a YTD gain of only 8.26%. Recent wins of multiple Gen-3 AI R&D contracts and a post-market quote of $21.69 suggest some continued interest, though.

BKSY.US fell sharply during regular trading today, with the price gapping down at the open of $23.655, hitting a session low of $21.580, and closing at $21.860, down 10.04% from the prior close of $24.300. The selloff was fueled by a confluence of negative catalysts, notably insider selling of over $1 million in shares and a downgrade to Hold by Jefferies, which amplified bearish sentiment. The Q1 2026 earnings report further weighed on the stock, showing a 29.68% year-over-year decline in revenue to $20.774 million, a net loss widening to $29.663 million, and an EPS of -$0.8205. Despite a YTD gain of 4.95%, the stock price is now 58.68% below its 52-week high of $52.88 (May 28, 2026) and trades below both the 20-day MA of $26.406 and the 60-day MA of $34.771, indicating significant technical weakness. However, in the post-market session, shares rebounded to $24.500, suggesting some buying interest at the lower levels.